

CORCEPT THERAPEUTICS INC  
Form 8-K  
December 20, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of**  
**the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): December 19, 2013**

**Corcept Therapeutics Incorporated**  
**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**000-50679**  
**(Commission**  
**File Number)**

**77-0487658**  
**(I.R.S. Employer**  
**Identification Number)**

**149 Commonwealth Drive**

**Menlo Park, CA 94025**

**(Address of principal executive offices, with zip code)**

**(650) 327-3270**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On December 19, 2013, the Board of Directors (the Board) of Corcept Therapeutics Incorporated (the Company) appointed Joseph K. Belanoff, M.D., age 56, as President of the Company, effective January 1, 2014, following the retirement of Robert L. Roe, M.D. Dr. Belanoff will continue to serve as the Company's Chief Executive Officer and as a member of the Board. As previously announced on the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2013, Dr. Roe will continue to serve as the Company's President until December 31, 2013, the effective date of his retirement.

Dr. Belanoff is a co-founder of the Company and has served as a member of the Board and as the Company's Chief Executive Officer since 1999. Dr. Belanoff is currently a clinical faculty member and has held various positions in the Department of Psychiatry and Behavioral Sciences at Stanford University since 1992. From 1997 to 2001, he served as the Director of Psychopharmacology at the outpatient division of the Palo Alto Veterans Affairs Hospital. Dr. Belanoff received his B.A. from Amherst College and his M.D. from Columbia University's College of Physicians & Surgeons.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORCEPT THERAPEUTICS  
INCORPORATED**

By: /s/ G. Charles Robb  
Name: G. Charles Robb  
Title: Chief Financial Officer

Date: December 20, 2013